Results 91 to 100 of about 16,063 (220)

Magnesium Ions Inhibit the Expression of Tumor Necrosis Factor α and the Activity of γ-Secretase in a β-Amyloid Protein-Dependent Mechanism in APP/PS1 Transgenic Mice

open access: yesFrontiers in Molecular Neuroscience, 2018
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by cognitive impairment. The neuropathological features of AD are the aggregation of extracellular amyloid β-protein (Aβ) and tau phosphorylation.
Xin Yu   +6 more
doaj   +1 more source

Correlation of Serum BACE1 With Emergence Delirium in Postoperative Patients: A Preliminary Study

open access: yesFrontiers in Aging Neuroscience, 2020
Background: The mechanism underlying delirium, a common acute fluctuating mental state, may be related to the activation of a neuroinflammatory response.
Chunyan Ye   +6 more
doaj   +1 more source

Emerging Roles of ADAM and ADAMTS Metalloproteinases in Cancer [PDF]

open access: yes, 2008
A disintegrin and metalloproteinases (ADAMs) are a recently discovered family of proteins that share the metalloproteinase domain with matrix metalloproteinases (MMPs).
Cataldo, Didier   +8 more
core   +1 more source

Human iPSC‐derived GABAergic interneuron transplantation restores circuit balance and cognitive function in an Alzheimer's disease model

open access: yesAlzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) is characterized by disrupted excitatory–inhibitory (E:I) balance and impaired synaptic function, yet current treatments fail to repair these fundamental circuit impairments. METHODS Human induced pluripotent stem cell‐derived post‐mitotic medial ganglionic eminence‐originated inhibitory neurons (MGE‐pINs)
Xinzhe Zhang   +8 more
wiley   +1 more source

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

open access: yesCancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi   +3 more
wiley   +1 more source

Dysregulated ADAM10-Mediated Processing of APP during a Critical Time Window Leads to Synaptic Deficits in Fragile X Syndrome [PDF]

open access: yes, 2016
© 2015 Elsevier Inc. The Fragile X mental retardation protein (FMRP) regulates neuronal RNA metabolism, and its absence or mutations leads to the Fragile X syndrome (FXS).
Bagni, Claudia   +2 more
core   +1 more source

AS1842856 Reduces β‐Amyloid Burden via Inhibiting PLA2G4A‐Mediated Lysosomal Dysfunction in APP/PS1 Mice

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.
AS1842856 reduces intracellular levels of GSK3α/β by binding to them and promoting their exocytosis. This reduction leads to diminished GSK3β‐mediated activation of NF‐κB, resulting in decreased transcription of PLA2G4A and reduced lysosomal damage. Ultimately, this enhances lysosomal degradation of Aβ, lowering Aβ load in APP/PS1 mice.
Da‐Long He   +5 more
wiley   +1 more source

Different types of γ-secretes complexes and their effect on substrate processing [PDF]

open access: yes, 2012
The γ-secretase complex is a transmembrane aspartyl protease that generates the Alzheimer disease (AD) related amyloid β-peptide (Aβ) from the amyloid precursor protein (APP). The γ- secretase complex cleaves APP at two different sites (γ- and ε-sites)
Pamrén, Annelie
core   +1 more source

When is Sirt1 activity bad for dying neurons? [PDF]

open access: yes, 2013
10.3389/fncel.2013.00186Frontiers in Cellular ...
Ng, F., Tang, B.L.
core   +2 more sources

TRAFFICKING OF ALPHA SECRETASE ADAM10: NEW INSIGHTS INTO THE MOLECULAR MECHANISM OF MODULATION

open access: yes, 2012
ADAM10 (a disintegrin and metalloproteinase 10) is the most accredited candidate as alpha-secretase in the amyloid cascade, since it prevents Abeta formation. ADAM10 is synthesized in an inactive form, which is proteolytically activated during its forward transport along the secretory pathway and at the plasma membrane.
openaire   +2 more sources

Home - About - Disclaimer - Privacy